Replies to post #163030 on Amarin Corp Plc (AMRN)

[KCSVEN]

But press release says nothing to that effect:

Amarin intends to use the net proceeds from the offering (1) to support the ongoing commercialization of Vascepa following REDUCE-IT results, including (i) seeking regulatory approval to expand the approved label for Vascepa based on the cardioprotective effect of Vascepa demonstrated in the REDUCE-IT study, beginning with submission of an sNDA to the FDA in early 2019, (ii) expansion of our sales force, and (iii) support of expanded commercial operations; (2) to increase commercial supply of Vascepa from third-party drug product suppliers; and (3) for general corporate purposes.

[jessellivermore]

raist..

Pharmakon is not a loan rather a complicated deal in which Amarin sold their patents to Pharmakon under a number of conditions..one being that Pharmakon would not sell the patents to a third party ...Unless the company failed...There is a very complicated payback schedule depending on how well the company was doing....

I'm not going into all the details. And don't know exactly how much Amarin owes Pharmakon..

":>) JL